Dacomitinib Drug Asset Due Diligence Report 2026

This Dacomitinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

171

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Dacomitinib can convert its Small molecule drug profile and EGFR L858R x EGFR-Ex19del x HER4 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Dacomitinib (query alias: dacomitinib)
Modality / target	Small molecule drug; EGFR L858R x EGFR-Ex19del x HER4; EGFR exon 19 deletion inhibitors, EGFR exon 21 L858R mutation inhibitors, HER4 antagonists
Highest global status	Approved
Originator	Pfizer Inc.
Active developers	Pfizer Inc., Pfizer Europe MA EEIG, Pfizer Pharmaceuticals Korea Ltd.

The MCP disease footprint includes EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer, EGFR exon 21 Substitution Mutant Non-small Cell Lung Cancer, Locally Advanced Lung Non-Small Cell Carcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06486142	Phase 3	Recruiting	200	Progression-free survival (PFS)
ChiCTR2500114068	Early Phase 1	Pending	30	mPFS, Median Progress Free Survival
CTR20244444	Not Applicable	已完成	60	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

16P - Dacomitinib in advanced NSCLC patients with uncommon EGFR mutations: A multicenter, single-arm, phase II study and biomarker analysis (DANCE study)

Phase 2; n=30; evaluation: Positive. Reported fields: ORR = 80.0 % ( 61.4 - 92.3)

Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation–positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study

Not Applicable; n=299; evaluation: Positive. Reported fields: Adverse Event: diarrhea = n = 81 [27.1 %]

638P - Dacomitinib with or without dose titration in treatment naïve advanced EGFR mutated NSCLC: Primary analysis of the ATORG-003 phase II trial

Phase 2; n=118; evaluation: Positive. Reported fields: - Met; PFS(12-month) = 60 % Met

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Dacomitinib addresses EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer, EGFR exon 21 Substitution Mutant Non-small Cell Lung Cancer, Locally Advanced Lung Non-Small Cell Carcinoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 171 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: EGFR L858R x EGFR-Ex19del x HER4 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-07-14	Dizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy	Approved	US$600.0M upfront; US$900.0M milestones
2026-05-18	全面强化肺癌治疗版图！复宏汉霖引进正大丰海/江苏创特三代口服EGFR-TKI	NDA/BLA	Financial terms not disclosed
2026-02-26	Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics	Preclinical	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO